Highlights
- Market Cap
- $543.46M
- Enterprise Value
- $489.27M
- EPS (TTM)
- -$4.81
- Total Revenue (TTM)
- $70.41M
- Gross Profit (TTM)
- $63.04M
- EBITDA (TTM)
- -$302.71M
- Year Range
- $6.14 - $9.36
- ROA (TTM)
- -71.22%
- ROE (TTM)
- -81.68%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Sage Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Sage Therapeutics, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 33.52% | 0.69% | 8.90% | -8.30% | -11.39% | 41.18% | -4.82% | 59.85% | |||||
| 2024 | 18.32% | -16.22% | -12.76% | -25.61% | -20.30% | -2.25% | 0.83% | -23.01% | -14.35% | -15.79% | -10.03% | -0.73% | -74.94% |
| 2023 | 16.26% | -6.09% | 0.77% | 16.42% | 1.33% | -5.01% | -26.24% | -42.33% | 2.90% | -8.99% | 4.54% | 10.67% | -43.18% |
| 2022 | -7.33% | -7.74% | -8.99% | -4.77% | -0.79% | 3.29% | 6.53% | 9.44% | 3.98% | -3.83% | 8.98% | -7.07% | -10.34% |
| 2021 | -6.77% | 5.39% | -11.94% | 5.22% | -11.63% | -18.38% | -23.02% | 5.67% | -4.11% | -8.91% | -3.59% | 9.33% | -50.83% |
| 2020 | -8.19% | -29.09% | -38.89% | 35.72% | -8.36% | 16.41% | 9.60% | 15.08% | 16.55% | 20.06% | 0.97% | 16.76% | 19.84% |
Benchmark Metrics
Sage Therapeutics, Inc. has an annualized alpha of -0.76%, beta of 1.30, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since July 21, 2014.
- This stock participated in 154.07% of S&P 500 Index downside but only 60.87% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.76%
- Beta
- 1.30
- R²
- 0.10
- Upside Capture
- 60.87%
- Downside Capture
- 154.07%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sage Therapeutics, Inc. (SAGE) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sage Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sage Therapeutics, Inc. was 97.51%, occurring on Nov 18, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.51% | Feb 2, 2018 | 1710 | Nov 18, 2024 | — | — | — |
| -68.91% | Jun 10, 2015 | 265 | Jun 27, 2016 | 279 | Aug 4, 2017 | 544 |
| -31.41% | Sep 12, 2017 | 33 | Oct 26, 2017 | 10 | Nov 9, 2017 | 43 |
| -21.44% | Dec 8, 2014 | 6 | Dec 15, 2014 | 16 | Jan 8, 2015 | 22 |
| -20.66% | Aug 12, 2014 | 29 | Sep 22, 2014 | 8 | Oct 2, 2014 | 37 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sage Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sage Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SAGE relative to other companies in the Biotechnology industry. Currently, SAGE has a P/S ratio of 7.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SAGE in comparison with other companies in the Biotechnology industry. Currently, SAGE has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |